Literature DB >> 21160754

Stopping the cardiovascular disease continuum: Focus on prevention.

Steven G Chrysant1.   

Abstract

The cardiovascular disease continuum (CVDC) is a sequence of events, which begins from a host of cardiovascular risk factors that consists of diabetes mellitus, dyslipidemia, hypertension, smoking and visceral obesity. If it is not intervened with early, it inexorably progresses to atherosclerosis, coronary artery disease, myocardial infarction, left ventricular hypertrophy, and left ventricular dilatation, which lead to left ventricular diastolic or systolic dysfunction and eventually end-stage heart failure and death. Treatment intervention at any stage during its course will either arrest or delay its progress. In this editorial, the cardiovascular risk factors that initiate and perpetuate the CVDC are briefly discussed, with an emphasis on their early prevention or aggressive treatment.

Entities:  

Keywords:  Cardiovascular disease continuum; Diabetes mellitus; Dyslipidemia; Hypertension; Obesity; Smoking

Year:  2010        PMID: 21160754      PMCID: PMC2999025          DOI: 10.4330/wjc.v2.i3.43

Source DB:  PubMed          Journal:  World J Cardiol


  68 in total

Review 1.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology.

Authors:  Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu
Journal:  JAMA       Date:  2009-05-27       Impact factor: 56.272

Review 2.  Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.

Authors:  Steven G Chrysant
Journal:  Clin Ther       Date:  2008       Impact factor: 3.393

3.  Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study.

Authors:  Kristina Dunder; Lars Lind; Björn Zethelius; Lars Berglund; Hans Lithell
Journal:  BMJ       Date:  2003-03-29

4.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

5.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

6.  Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association.

Authors:  Harmon Eyre; Richard Kahn; Rose Marie Robertson; Nathaniel G Clark; Colleen Doyle; Yuling Hong; Ted Gansler; Thomas Glynn; Robert A Smith; Kathryn Taubert; Michael J Thun
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

7.  Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study.

Authors:  Seung-Han Suk; Ralph L Sacco; Bernadette Boden-Albala; Jian F Cheun; John G Pittman; Mitchell S Elkind; Myunghee C Paik
Journal:  Stroke       Date:  2003-05-29       Impact factor: 7.914

8.  Smoking and myocardial infarction.

Authors:  C Wilhelmsson; J A Vedin; D Elmfeldt; G Tibblin; L Wilhelmsen
Journal:  Lancet       Date:  1975-02-22       Impact factor: 79.321

9.  Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.

Authors:  F Turnbull; B Neal; M Pfeffer; J Kostis; C Algert; M Woodward; J Chalmers; A Zanchetti; S MacMahon
Journal:  J Hypertens       Date:  2007-05       Impact factor: 4.844

10.  The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.

Authors:  Stephan Lüders; Joachim Schrader; Jürgen Berger; Thomas Unger; Walter Zidek; Michael Böhm; Martin Middeke; Wolfgang Motz; Cornelia Lübcke; Andrea Gansz; Ludmer Brokamp; Roland E Schmieder; Peter Trenkwalder; Herrmann Haller; Peter Dominiak
Journal:  J Hypertens       Date:  2008-07       Impact factor: 4.844

View more
  3 in total

Review 1.  Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.

Authors:  Melanie J Davies; Heinz Drexel; François R Jornayvaz; Zoltan Pataky; Petar M Seferović; Christoph Wanner
Journal:  Cardiovasc Diabetol       Date:  2022-08-04       Impact factor: 8.949

2.  Clinical lipid control success rate before and after percutaneous coronary intervention in iran; a single center study.

Authors:  Seyed Kianoosh Hosseini; Maryam Tahvildari; Mohammad Javad Alemzadeh Ansari; Manouchehr Nakhjavani; Alireza Esteghamati; Masoumeh Lotfi Tokaldany
Journal:  Iran Red Crescent Med J       Date:  2013-06-05       Impact factor: 0.611

3.  Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index.

Authors:  P Jane McDowell; John H Stone; Yuqing Zhang; Kirsty Honeyford; Louise Dunn; R Jayne Logan; Lorcan P A McGarvey; Claire A Butler; Liam G Heaney
Journal:  Eur Respir J       Date:  2022-01-20       Impact factor: 16.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.